About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Serum Antimullerian Hormone Levels in Patients Who Underwent Hayman Suture

Clinicaltrials.gov identifier NCT03930407

Recruitment Status Recruiting

First Posted April 29, 2019

Last update posted April 29, 2019

Study Description

Brief summary:

From patient charts we will review patients who had undergone cesarean section within the last 6 months and identify those who received a The Hayman uterine compression suture for uterine atony. We will also select patients who delivered a baby without recieving a Hayman suture to create a control group. Patietns will be grouped as Hayman Group if they recevied a Hayman suture during C/S and control group if thay had not recevied a Hayman suture. We will then check patient charts for post-cesarean outpatient clinic visit and select those who received ovarian reserve evaluation via hormones and antral follicle count during the visits. Finally, we are planning to investigate any correlation between Hayman suture and ovarian dysfunction.

  • Condition or Disease:Uterine Atony With Hemorrhage
    Ovarian Dysfunction
  • Intervention/Treatment: Procedure: The Hayman uterine compression suture.
  • Phase: N/A
Detailed Description

Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atoy dıring cesarean section. However, since the technique is relatively new, data on its safety and efficacy arelimited to a few case reports. several complications including cavity obliteration, blood entrapment and infections have been described. However, data regarding the ovarioan function is lacking.

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 120 participants
  • Observational Model: Case-Control
  • Time Perspective: Retrospective
  • Official Title: Serum Antimullerian Hormone Levels in Patients Who Underwent Hayman Suture for Uterine Atony During Cesarean Section
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: June 2019
  • Estimated Study Completion Date: June 2019
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Hayman group
Who had undergone cesarean section within the last 6 months and received a The Hayman uterine compression suture for uterine atony.
Procedure: The Hayman uterine compression suture.
Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
Outcome Measures
  • Primary Outcome Measures: 1. Change in anti-mullerian hormone level from baseline (precesarean) to post-cesarean [ Time Frame: Before cesarean section and at any follow-up visit within 6 months of cesarean section ]
    ng/dl
  • 2. Change in follicle stimulating hormone level from baseline (precesarean) to post-cesarean [ Time Frame: Before cesarean section and at any follow-up visit within 6 months of cesarean section ]
    IU/L
  • 3. Change in luteinizing hormone level from baseline (precesarean) to post-cesarean [ Time Frame: Before cesarean section and at any follow-up visit within 6 months of cesarean section ]
    mU/mL
  • Secondary Outcome Measures: 1. Antral follicle count in the two study groups [ Time Frame: At any follow-up visit within 6 months of cesarean section ]
    number
Eligibility Criteria
  • Ages Eligible for Study: 18 to 40 Years (Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers:
  • Sampling Method: Probability Sample
  • Study Population: Patients who had undergone uterine artery ligation during cesarean section. Control group is age-matched postpartum patients.
Criteria

Inclusion Criteria:

- age 18- 40 years

- no systemic or endocrine diseases

- patients who had uterine artery ligation due to atony

- healthy postpartum patients as controls

Exclusion Criteria:

- patients with Polyctsitic over syndrome

- Pregnancy with IVF or oocyte donation

- Obese patients

- patients with previous/present endometriosis

Contacts and Locations
Contacts

Contact: Aysu Akca, MD +905053868637 aysuakca4@gmail.com

Locations

Turkey, Please Enter The State Or Province
Department of Obstetrics and Gynecology, University of Health Sciences, Faculty of Medicine, Kanuni Sultan Suleyman Hospital,
Istanbul

Sponsors and Collaborators

Kanuni Sultan Suleyman Training and Research Hospital

Investigators

Principal Investigator: Asyu Akca Kanuni Sultan Suleyman Hospital

More Information
  • Responsible Party: Kanuni Sultan Suleyman Training and Research Hospital
  • ClinicalTrials.gov Identifier: NCT03930407 History of Changes
  • Other Study ID Numbers: AYSUAKCA1
  • First Posted: April 29, 2019 Key Record Dates
  • Last Update Posted: April 29, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Kanuni Sultan Suleyman Training and Research Hospital: Cesarean section
    Uterine atony
    Hayman uterine compression suture
    Follicle-stimulating hormone
    Luteinizing hormone
    Antral follicle count
  • Additional relevant MeSH terms: Uterine Inertia Hemorrhage